Myriad Genetics (MYGN) CEO gets 618,557 RSUs, 47,120 shares withheld

Rhea-AI Filing Summary

Myriad Genetics President and CEO Samraat S. Raha reported equity compensation and related tax withholding transactions in common stock. On March 12, 2026, he received a grant of 618,557 time-based restricted stock units, each representing one future share, vesting in three equal annual installments starting on the first anniversary of the grant date.

On March 13 and 14, 2026, a total of 47,120 shares of common stock were withheld by the company at $4.66 per share to cover tax obligations from previously vesting restricted stock units. After these transactions, Raha directly owns 1,064,541 shares of Myriad Genetics common stock.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Raha Samraat S.

(Last) (First) (Middle)

322 NORTH 2200 WEST

(Street)

SALT LAKE CITY UT 84116

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
MYRIAD GENETICS INC [ MYGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

3. Date of Earliest Transaction (Month/Day/Year)
03/12/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/12/2026		A		618,557(1)	A	$0	1,111,661	D
Common Stock	03/13/2026		F		36,304(2)	D	$4.66	1,075,357	D
Common Stock	03/14/2026		F		10,816(2)	D	$4.66	1,064,541	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Consists of time-based restricted stock units granted pursuant to the Issuer's 2017 Employee, Director and Consultant Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock and vests in three equal annual installments beginning on the first anniversary of the grant date.

2. Represents shares of Common Stock withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units previously granted to the Reporting Person. The number of shares withheld was determined based on the closing price of Issuer's Common Stock on March 13, 2026.

Remarks:

	By: Justin Hunter For: Samraat S. Raha	03/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Myriad Genetics (MYGN) CEO report?

Myriad Genetics CEO Samraat S. Raha reported a grant of 618,557 restricted stock units and tax-related withholdings of 47,120 shares of common stock. These transactions reflect equity compensation and associated tax withholding rather than open-market buying or selling.

How many RSUs did the Myriad Genetics CEO receive in this Form 4?

Samraat S. Raha received 618,557 time-based restricted stock units of Myriad Genetics common stock. Each unit represents a contingent right to one share and vests in three equal annual installments, beginning on the first anniversary of the March 12, 2026 grant date.

Why were 47,120 Myriad Genetics shares withheld from the CEO?

The 47,120 shares were withheld by Myriad Genetics to satisfy tax withholding obligations related to previously granted RSUs that vested. The number of shares was based on the $4.66 closing price of the company’s common stock on March 13, 2026.

Did the Myriad Genetics CEO sell any shares on the open market?

No open-market sales are disclosed. The Form 4 shows F-code transactions, which are shares withheld by the issuer to cover tax liabilities from vesting restricted stock units, rather than discretionary sales initiated in the market.

What is the Myriad Genetics CEO’s ownership after these transactions?

Following the reported grant and tax-withholding dispositions, Samraat S. Raha directly owns 1,064,541 shares of Myriad Genetics common stock. This reflects his post-transaction equity position as shown in the Form 4’s share balance fields.

How do the CEO’s new RSUs at Myriad Genetics vest over time?

The 618,557 restricted stock units vest in three equal annual installments. Vesting begins on the first anniversary of the March 12, 2026 grant date, with each installment delivering common shares as long as vesting conditions are met.